Detalles de la búsqueda
1.
Significant dose Escalation of Idarubicin in the treatment of aggressive Non- Hodgkin Lymphoma leads to increased hematotoxicity without improvement in efficacy in comparison to standard CHOEP-14: 9-year follow up results of the CIVEP trial of the DSHNHL.
Springerplus
; 3: 5, 2014 Jan 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-24455463
Resultados
1 -
1
de 1
1
Próxima >
>>